| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc. | Director | Common Stock | 2.5K | $137K | $54.75 | Jun 26, 2024 | Direct |
| eFFECTOR Therapeutics, Inc. | Chief Business Officer | Stock Option (Right to Buy) | 150K | Jun 20, 2022 | Direct | ||
| Janux Therapeutics, Inc. | Director | Stock Option (right to buy) | 8.35K | Jun 26, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | Jun 26, 2024 | 2 | $0 | 4 | Jun 28, 2024 | Director |
| GFOR | NKGen Biotech, Inc. | Sep 29, 2023 | 0 | $0 | 3 | Oct 10, 2023 | Director |
| JANX | Janux Therapeutics, Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
| EFTR | eFFECTOR Therapeutics, Inc. | Jun 20, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Chief Business Officer |
| JANX | Janux Therapeutics, Inc. | Jun 14, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director |
| EFTR | eFFECTOR Therapeutics, Inc. | Jan 20, 2022 | 1 | $0 | 4 | Jan 24, 2022 | Chief Business Officer |
| JANX | Janux Therapeutics, Inc. | Sep 7, 2021 | 1 | $0 | 4 | Sep 9, 2021 | Director |
| JANX | Janux Therapeutics, Inc. | Sep 7, 2021 | 0 | $0 | 3 | Sep 9, 2021 | Director |
| EFTR | eFFECTOR Therapeutics, Inc. | Aug 25, 2021 | 9 | $0 | 4 | Aug 27, 2021 | Chief Business Officer |
| EFTR | eFFECTOR Therapeutics, Inc. | Aug 25, 2021 | 0 | $0 | 3 | Aug 27, 2021 | Chief Business Officer |